Evidence map›Paper›PMID 31413314›Full record

ArticleThe Journal of antibiotics2019

Muraminomicins, new lipo-nucleoside antibiotics from Streptosporangium sp. SANK 60501-structure elucidations of muraminomicins and supply of the core component for derivatization.

Yoko Fujita, Yoshiko Kagoshima, Takeshi Masuda, Masaaki Kizuka, Yasumasa Ogawa, Shuichi Endo, Hideaki Nishigoori, Kazuko Saito, Kunio Takasugi, Masami Miura and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Yoko FujitaOrganic Synthesis Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan. fujita.yoko.dx@rdn.daiichisankyo.co.jp.
Yoshiko KagoshimaMedicinal Chemistry Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Takeshi MasudaBiologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd., Gumma, Japan.
Masaaki KizukaOrganic Synthesis Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.
Yasumasa OgawaDaiichi Sankyo Biotech Co., Ltd., Saitama, Japan.
Shuichi EndoOnahama Plant, Daiichi Sankyo Chemical Pharma Co., Ltd., Fukushima, Japan.
Hideaki NishigooriOnahama Plant, Daiichi Sankyo Chemical Pharma Co., Ltd., Fukushima, Japan.
Kazuko SaitoCore Technology Research Loboratories, Sankyo Co, Ltd., Tokyo, Japan.
Kunio TakasugiCore Technology Research Loboratories, Sankyo Co, Ltd., Tokyo, Japan.
Masami MiuraAnalytical & Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., Kanagawa, Japan.
Ryo MurakamiOncology Research LaboratoriesII, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Yasunori MuramatsuOrganic Synthesis Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.
Akane TokumitsuBiological Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
Tetsufumi KogaVaccine Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Mayumi IizukaOrganic Synthesis Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.
Azusa AoyagiAnalytical & Quality Evaluation Research Laboratories, Daiichi Sankyo Co., Ltd., Kanagawa, Japan.
Toshihiro SuzukiCore Technology Research Loboratories, Sankyo Co, Ltd., Tokyo, Japan.
Takashi SuzukiTatebayashi Plant, Daiichi Sankyo Chemical Pharma Co., Ltd., Saitama, Japan.
Yasuhiro SuzukiBiologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd., Gumma, Japan.
Osamu IshidaPharmaceutical Technology Laboratories, Sankyo Co., Ltd., Fukushima, Japan.
Toru NakahiraCore Technology Research Loboratories, Sankyo Co, Ltd., Tokyo, Japan.
Shunichi MiyakoshiCore Technology Research Loboratories, Sankyo Co, Ltd., Tokyo, Japan.
Toshiyuki KonosuResearch Function, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Toshio TakatsuOrganic Synthesis Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We screened for bacterial phospho-N-acetylmuramyl-pentapeptide-translocase (MraY: EC 2.7.8.13) inhibitors with the aim of discovering novel antibiotics and observed inhibitory activity in the culture broth of an actinomycete, SANK 60501. The active compounds, muraminomicins A, B, C, D, E

Indexed as

ActinomycetalesAnti-Bacterial AgentsBacterial ProteinsEnzyme InhibitorsFatty AcidsFermentationGram-Positive BacteriaMagnetic Resonance SpectroscopyMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipTransferasesTransferases (Other Substituted Phosphate Groups)Anti-Bacterial AgentsBacterial ProteinsEnzyme InhibitorsFatty AcidsmraY protein, BacteriaTransferasesTransferases (Other Substituted Phosphate Groups)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.